KR880003620A - 치료용 합성물 및 치료법(Therapeutic Composition and Method) - Google Patents

치료용 합성물 및 치료법(Therapeutic Composition and Method) Download PDF

Info

Publication number
KR880003620A
KR880003620A KR870009971A KR870009971A KR880003620A KR 880003620 A KR880003620 A KR 880003620A KR 870009971 A KR870009971 A KR 870009971A KR 870009971 A KR870009971 A KR 870009971A KR 880003620 A KR880003620 A KR 880003620A
Authority
KR
South Korea
Prior art keywords
calcium
gla
daily
bone
hypertension
Prior art date
Application number
KR870009971A
Other languages
English (en)
Other versions
KR970002608B1 (ko
Inventor
프레드릭 호로빈 데이비드
와이.솅후앙
Original Assignee
스테판 제랄드 웨트모어.
에파몰 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스테판 제랄드 웨트모어., 에파몰 리미티드 filed Critical 스테판 제랄드 웨트모어.
Publication of KR880003620A publication Critical patent/KR880003620A/ko
Application granted granted Critical
Publication of KR970002608B1 publication Critical patent/KR970002608B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

내용 없음

Description

치료용 합성물 및 치료법(Therapeutic Composition and Method)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. 매일 1㎎에서 100g의 GLA와 1㎎에서 20g의 칼슘을 복용하여 동화할수 있는 1회 복용단위로 복용하도록 주어진 감마-리놀레닉산(GLA)과 칼슘의 화합물.
  2. 제1항에 따른 GLA와 칼슘의 화합물을 각기 150㎎에서 3g과 500㎎에서 3g을 매일 복용하는 것을 특징으로 하는 것.
  3. 제1항 또는 제2항과 같이 주어진 GLA 및 칼슘으로 프리멘스트루얼 신드롬 또는 고혈압(premenstrual syndrome or hypertension)으로 인해 뼈에서 칼슘의 손실이 손실이 수반되는 골다공증 및 뼈에 생기는 다른 질병을 치료하기 위한 약제를 제조하는 방법.
  4. 프리멘스트루얼 신드롬 또는 고혈압으로 인해 뼈에서 칼슘의 손실이 수반되는 골다공증 및 뼈에 생기는 다른 질병을 치료하기 위해 GLA와 칼슘을 동화할 수 있는 복용단위의 형태로 매일 1㎎에서 100g의 GLA와 1㎎에서 20g의 칼슘을 복용하는 방법.
  5. 제4항에 따른 방법에 있어서, 각기 매일 150㎎에서 3g과 500㎎에서 3g을 매일 복용하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870009971A 1986-09-10 1987-09-09 감마-리놀렌산과 칼슘을 함유하는 치료학적 조성물 KR970002608B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868621816A GB8621816D0 (en) 1986-09-10 1986-09-10 Therapeutic composition
GB86/21816 1986-09-10

Publications (2)

Publication Number Publication Date
KR880003620A true KR880003620A (ko) 1988-05-28
KR970002608B1 KR970002608B1 (ko) 1997-03-06

Family

ID=10603976

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870009971A KR970002608B1 (ko) 1986-09-10 1987-09-09 감마-리놀렌산과 칼슘을 함유하는 치료학적 조성물

Country Status (16)

Country Link
US (1) US4855136A (ko)
EP (1) EP0261814B1 (ko)
JP (1) JP2775627B2 (ko)
KR (1) KR970002608B1 (ko)
AT (1) ATE69166T1 (ko)
AU (1) AU598853B2 (ko)
CA (1) CA1289887C (ko)
DE (1) DE3774382D1 (ko)
ES (1) ES2044947T4 (ko)
FI (1) FI873905A (ko)
GB (1) GB8621816D0 (ko)
GR (1) GR3003153T3 (ko)
HK (1) HK129493A (ko)
IE (1) IE60418B1 (ko)
SG (1) SG115093G (ko)
ZA (1) ZA876483B (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
GB2254556B (en) * 1991-04-11 1995-04-12 Fisons Plc Formulations containing linolenic acid
GB9112052D0 (en) * 1991-06-05 1991-07-24 Efamol Holdings Fatty acid treatment
GB9217780D0 (en) * 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
US5888541A (en) * 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
US5516801A (en) * 1992-08-21 1996-05-14 Scotia Holdings Plc Fatty acid treatment for ectopic calcium deposition
DE4240713C1 (de) * 1992-12-03 1994-01-27 Georg Prof Dr Dietz Verwendung eines Gemischs aus Calciumhydroxid und Oleum pedum tauri zur Kollageneubildung in vivo
DE4330664A1 (de) * 1993-09-10 1995-03-16 Beiersdorf Ag Verwendungen von Pflanzenölen
EP0711503A3 (en) * 1994-11-14 1997-11-26 Scotia Holdings Plc Milk fortified with GLA and/or DGLA
US5804210A (en) * 1996-08-07 1998-09-08 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein
JP4129566B2 (ja) 1997-09-05 2008-08-06 大塚製薬株式会社 肝臓脂肪蓄積抑制組成物及び肝臓脂肪蓄積抑制用食品添加剤
US20070141181A1 (en) 1998-02-13 2007-06-21 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US6451771B1 (en) 1999-02-12 2002-09-17 Nutramax Laboratories, Inc. Use of anabolic agents anti-catabolic agents and antioxidant agents for protection treatment and repair of connective tissues in humans and animals
US6797289B2 (en) * 1998-02-13 2004-09-28 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
CA2442692A1 (en) * 2001-03-30 2002-10-10 The Nisshin Oillio, Ltd. Bone metabolism improving agents
JP4728561B2 (ja) * 2001-05-14 2011-07-20 マーテック バイオサイエンシーズ コーポレーション 植物種子および微生物由来のステアリドン酸およびγ−リノレン酸を含む極性脂質リッチ画分の精製および使用方法
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
US8728546B1 (en) * 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3075880A (en) * 1961-03-29 1963-01-29 Roth Lester Hugh Bone and tissue repair
IE47777B1 (en) * 1978-01-23 1984-06-13 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
US4273763A (en) * 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
IE49783B1 (en) * 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
US4421743A (en) * 1979-09-14 1983-12-20 T & R Chemicals, Inc. Antihypertension treatment
FR2490631A1 (fr) * 1980-09-24 1982-03-26 Roussel Uclaf Nouvelle composition lipidique utilisable en dietetique, reanimation et therapeutique
US4642317B1 (en) * 1981-06-16 1996-12-31 Ohio Agricultural Res & Dev Process for feeding ruminant animals and composition for use therein
DE3368377D1 (en) * 1982-04-16 1987-01-29 Nestle Sa Lipid composition for oral, enteral or parenteral feeding
DE3346525A1 (de) * 1983-12-22 1985-07-04 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutische zubereitung mit speziellen 1,2-diacyl-glycero-3-phosphocholinen zur behandlung von erkrankungen im magen-darmbereich
GB8425006D0 (en) * 1984-10-03 1984-11-07 Efamol Ltd Composition of copper/fatty acids
US4695590A (en) * 1986-05-05 1987-09-22 California Health Technologies Method for retarding aging

Also Published As

Publication number Publication date
EP0261814A2 (en) 1988-03-30
SG115093G (en) 1994-01-21
ZA876483B (en) 1989-08-30
CA1289887C (en) 1991-10-01
IE60418B1 (en) 1994-07-13
EP0261814B1 (en) 1991-11-06
US4855136A (en) 1989-08-08
KR970002608B1 (ko) 1997-03-06
GB8621816D0 (en) 1986-10-15
IE872333L (en) 1988-03-10
JPS6377817A (ja) 1988-04-08
FI873905A0 (fi) 1987-09-09
HK129493A (en) 1993-12-03
AU7793887A (en) 1988-03-17
DE3774382D1 (de) 1991-12-12
ATE69166T1 (de) 1991-11-15
GR3003153T3 (en) 1993-02-17
FI873905A (fi) 1988-03-11
AU598853B2 (en) 1990-07-05
EP0261814A3 (en) 1989-02-01
ES2044947T3 (es) 1994-01-16
JP2775627B2 (ja) 1998-07-16
ES2044947T4 (es) 1996-07-16

Similar Documents

Publication Publication Date Title
KR880003620A (ko) 치료용 합성물 및 치료법(Therapeutic Composition and Method)
DK420385A (da) Antioestrogent laegemiddel til perkutan indgift
KR880010764A (ko) 과콜레스테롤혈중 치료용 혼합물
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
DE3682811D1 (de) Pharmazeutische zusammensetzung zur heilung und verhuetung kardiovaskularer krankheiten und verfahren zu ihrer herstellung.
DE69133077T2 (de) Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
KR890003390A (ko) 골다공증 및 관련된 장해의 치료방법
KR920702225A (ko) 약학 조성물
ATE114471T1 (de) Verfahren zur behandlung und vorbeugung des verlustes von knochenmasse.
TW200509955A (en) Pharmaceutical composition for prophylaxis or treatment of osteoporosis, and method to prepare the same
KR880009656A (ko) 국소 치근막 질환의 치료 또는 예방법
KR980700083A (ko) 골다공증 치료 주기용 키트(KIT for Osteoporosis Treatment Cycle)
KR890009868A (ko) 1-메틸-β-옥소-α-(페닐카바모일)-2- 피롤프로피오니트릴의 트로메트아민염
JPS54148090A (en) Peroral cholesterol-depressant
SU971250A1 (ru) Способ лечени гипогонадизма
CN1048893C (zh) 一种治疗骨质增生药油及制作方法
KR970058708A (ko) 엘-무스콘(l-muscone)의 의약용도
RU2001122084A (ru) Биологически активная добавка для профилактики и лечения гриппа "Фитогриппин"
JPS5249654A (en) Preliminary treatment of human and animal excrements with bacteria in intestines
KR880000094A (ko) 위염치료제
EP0261891A3 (en) Pharmaceutical compositions containing etiochiolandione
Bauer A new approach to treatment of various nail disorders
JPS56103114A (en) Drug for osteoporosis comprising 24r- hydroxycholecalciferol
KR890001567A (ko) 디플루니살 및 트로메타민-함유 조성물
KR900015616A (ko) 배나무 점무늬병 치료제.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

G160 Decision to publish patent application
B701 Decision to grant
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee